Berry Genomics plans to hold a controlling stake in YiYuan TongKang to provide integrated testing services for genetic diseases in newborns and children
I'm PortAI, I can summarize articles.
Berry Genomics announced that its wholly-owned subsidiary, Berry Health, plans to establish a holding subsidiary, YiYuan TongKang, with Mr. Li Wei in Zhengzhou, with a registered capital of 1 million yuan, in which Berry Health will hold 60%. The company will collaborate with public medical institutions to provide genetic disease testing services for newborns and children, with the future registered capital expected to be no less than 50 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments